The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder
Abstract
OBJECTIVE: Four studies using identical protocols evaluated the safety and efficacy of four novel, evidence-based targets for antipsychotic agents: a neurokinin (NK(3)) antagonist (SR142801), a serotonin 2A/2C (5-HT(2A/2C)) antagonist (SR46349B), a central cannabinoid (CB(1)) antagonist (SR141716), and a neurotensin (NTS(1)) antagonist (SR48692). METHOD: Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned in a 3:1:1 ratio to receive fixed doses of investigational drug, placebo, or haloperidol for 6 weeks. Primary efficacy variables included changes from baseline in total score on the Positive and Negative Syndrome Scale, severity of illness score on the Clinical Global Impression (CGI), and total score and psychosis cluster score on the Brief Psychiatric Rating Scale (BPRS). RESULTS: Significantly greater improvement in all primary efficacy variables was seen in the group receiving haloperidol than in the group receiving placebo at 6 weeks (endpoint analyses), indicating the validity of the study. The group receiving the NK(3) antagonist showed significantly greater improvement over baseline than the group receiving placebo as measured by Positive and Negative Syndrome Scale total score, CGI severity of illness score, and BPRS psychosis cluster score. Reductions in the Positive and Negative Syndrome Scale total and negative scores in the group receiving the 5-HT(2A/2C) antagonist were significantly larger than those in the group receiving placebo. The improvements in psychopathology produced by the NK(3) and 5-HT(2A/2C) antagonists were smaller than those produced by haloperidol, although the response to the NK(3) antagonist was positively correlated with plasma levels. The groups receiving the CB(1) and NTS(1) antagonists did not differ from the group receiving placebo on any outcome measure. All investigational drugs were well tolerated. CONCLUSIONS: The novel design used in this study permitted the use of a smaller number of patients receiving placebo to test the efficacy of the four novel compounds. The NK(3) and 5-HT(2A/2C) antagonists showed evidence of efficacy in the treatment of schizophrenia and schizoaffective disorder. Study limitations preclude a definitive conclusion on the efficacy of CB(1) and NTS(1) antagonists in the treatment of schizophrenia. Further study of these two promising nondopaminergic mechanisms to treat schizophrenia and schizoaffective disorder appears indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
A depression rating scale for schizophrenics
Addington, D., Addington, J., & Schissel, B. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90005-r · Cited by 1,269
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Self-citationStudies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Choudhary, M. S., Craigo, S., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592
Self-citationIchikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494
Self-citationElevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00008 · Cited by 432
Moghaddam, B., & Bunney, B. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01230.x · Cited by 402
Dean, B., Sundram, S., Bradbury, R., Scarr, E., & Copolov, D. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00552-2 · Cited by 383
Kuroki, T., Meltzer, H. Y., & Ichikawa, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38019-x · Cited by 351
Self-citationAnimal models of schizophrenia: a critical review.
Marcotte, E. R., Pearson, D. M., & Srivastava, L. K. (2001) · PubMed · Cited by 234
SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor
Emonds-Alt, X., Bichon, D., Ducoux, J. P., Heaulme, M., Miloux, B., Poncelet, M., Proietto, V., Van Broeck, D., Vilain, P., Neliat, G., et al. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00413-m · Cited by 218
Li, X.-M., Perry, K. W., Wong, D. T., & Bymaster, F. P. (1998) · Psychopharmacology · doi:10.1007/s002130050551 · Cited by 189
Millan, M. J., Brocco, M., Gobert, A., Joly, F., Bervoets, K., Rivet, J., Newman‐Tancredi, A., Audinot, V., & Maurel, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00858.x · Cited by 149
Rinaldi, M. L., Congy, C., Santucci, V., Simiand, J., Gautret, B., Neliat, G., Labeeuw, B., Fur, G. L., Soubrié, P., & Brelière, J. C. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10821-5 · Cited by 116
Marco, N., Thirion, A., Mons, G., Bougault, I., Fur, G. L., Soubrié, P., & Steinberg, R. (1998) · Neuropeptides · doi:10.1016/s0143-4179(98)90075-0 · Cited by 104
Binder, E. B., Kinkead, B. L., Owens, M. J., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01211-2 · Cited by 102
Duncan, G. E., Zorn, S. J., & Lieberman, J. A. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000581 · Cited by 100
Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics*
Barnes, T. R. E., & McPhillips, M. A. (1999) · The British Journal of Psychiatry · doi:10.1192/s0007125000298097 · Cited by 98
Collins, D. R., Pertwee, R. G., & Davies, S. N. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15889.x · Cited by 92
Alonso, R., Voutsinos‐Porche, B., Fournier, M., Labie, C., Steinberg, R., Souilhac, J., Fur, G. L., & Soubrié, P. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00675-7 · Cited by 83
Bonaccorso, S. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00311-1 · Cited by 80
Binder, E. B., Kinkead, B. L., Owens, M. J., Kilts, C. D., & Nemeroff, C. B. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00601.2001 · Cited by 73
A Comment on the "Amotivational Syndrome" in Marijuana Smokers
Kupfer, D. J., DETRE, T. P., Koral, J., & Fajans, P. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.12.1319 · Cited by 69
Poncelet, M., Barnouin, M. C., Brelière, J.-C., Fur, G. L., & Soubrié, P. (1999) · Psychopharmacology · doi:10.1007/s002130050987 · Cited by 66
Optimal Haloperidol Dosage in First-Episode Psychosis
Zhang-Wong, J., Zipursky, R. B., Beiser, M., & Bean, G. (1999) · The Canadian Journal of Psychiatry · doi:10.1177/070674379904400207 · Cited by 46
Jung, M., Michaud, J. C., Steinberg, R., Barnouin, M. C., Hayar, A. M., Mons, G., Souilhac, J., Emonds‐Alt, X., Soubrié, P., & Fur, G. L. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00150-9 · Cited by 43
Pharmacological and molecular targets in the search for novel antipsychotics
Scatton, B., & Sanger, D. J. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00008 · Cited by 39
Gueudet, C., Santucci, V., Soubri�, P., & Fur, G. L. (1999) · Synapse · doi:10.1002/(sici)1098-2396(199907)33:1<71::aid-syn7>3.0.co;2-2 · Cited by 29
Rinaldi, M. L., Bouaboula, M., Congy, C., Oury-Donat, F., Simiand, J., Shire, D. J., Casellas, P., Soubrié, P., Brelière, J.-C., & Fur, G. L. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90012-x · Cited by 29
Azzi, M., Nicot, A. B., Gully, D., et al. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90671-8 · Cited by 23
Alonso, R., Gnanadicom, H., Fréchin, N., Fournier, M., Fur, G. L., & Soubrié, P. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00506.x · Cited by 22
Recommended Haloperidol and Risperidone Doses in First-Episode Psychosis
McGorry, P. D. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1118 · Cited by 15
Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons
Michaud, J.-C., Gueudet, C., & Soubrié, P. (2000) · Neuroreport · doi:10.1097/00001756-200005150-00017 · Cited by 13
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
“This idea has fueled two large-scale clinical trials with CB1-type cannabinoid receptor antagonists in schizophrenia, which yielded, however, negative results.(10,11) A diametrically opposite view —”
ResultMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Metadata
- Authors
- Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group
- Venue
- American Journal of Psychiatry
- Published
- 2004-06-01
- Volume
- 161
- Issue
- 6
- Pages
- 975-984
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2106156723
- Cited by
- 330
- References
- 38
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.